Skip to main content

Table 2 Incidence and occurrence time of ≥ grade 2 HT and ≥ grade 3 HT

From: A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer

HT categories

Number(%)

Median(IQR, Range, day)

Grade ≥ 2 leukopenia

62 (63.9%)

29th day (IQR 21.75-39.5th day, Range 5-64th)

 

Grade ≥ 2 neutropenia

44 (45.4%)

42th day (IQR 28-49th day, Range 11-75th)

Grade ≥ 2 thrombocytopenia

19 (19.6%)

35th day (IQR 30-42th day, Range 20-47th)

Grade ≥ 2 anemia

31 (38.8%)

31th day (IQR 21-36th day, Range 9-63th)

Grade ≥ 3 leukopenia

26 (26.8%)

38th day (IQR 31.5-46.25th day, Range 20-56th)

Grade ≥ 3 neutropenia

14 (14.4%)

40th day (IQR 35.75-44.5th day, Range 11-64th)

Grade ≥ 3 thrombocytopenia

11 (11.3%)

35th day (IQR 34-44th day, Range 28-47th)

Grade ≥ 2 anemia

16 (16.5%)

41.5th day (IQR 35-45th day, Range 32-55th)